18-Methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
    12.
    发明申请
    18-Methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter 失效
    18-甲基-19-去甲-17-孕-4-烯-21,17-碳内酯,以及含有后者的药物制剂

    公开(公告)号:US20060252737A1

    公开(公告)日:2006-11-09

    申请号:US11321449

    申请日:2005-12-30

    IPC分类号: A61K31/58 C07J19/00

    CPC分类号: C07J19/00

    摘要: This invention describes the new 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones of general formula I in which Z means an oxygen atom, two hydrogen atoms, a grouping ═NOR or ═NNHSO2R, whereby R is a hydrogen atom or a straight-chain or branched-chain alkyl group with 1 to 4 or 3 to 4 carbon atoms, R4 is a hydrogen atom, a halogen atom, a methyl group, or a trifluoromethyl group, R6 and/or R7 can be in α- or β-position, and, independently of one another, mean a straight-chain or branched-chain alkyl group with 1 to 4 or 3 to 4 carbon atoms, or R6 means a hydrogen atom, and R7 means an α- or β-position, straight-chain or branched-chain alkyl group with 1 to 4 or 3 to 4 carbon atoms, or R6 and R7 each mean a hydrogen atom, or R6 and R7 together mean an α- or β-position methylene group or an additional bond. The new compounds have gestagenic and anti-mineralocorticoid action and are suitable for the production of pharmaceutical preparations, for example for oral contraception and the treatment of pre-, peri- and post-menopausal symptoms.

    摘要翻译: 本发明描述了通式I的新的18-甲基-19-去甲-17-孕甾-4-烯-21,17-碳内酯,其中Z表示氧原子,两个氢原子,-NOR或-NNHSO- R 2是氢原子或具有1至4或3至4个碳原子的直链或支链烷基,R 4是氢原子 ,卤素原子,甲基或三氟甲基,R 6和/或R 7可以是α-或β-位,并且独立地为一个 另一个是指具有1至4或3至4个碳原子的直链或支链烷基,或R 6表示氢原子,R 7表示 具有1至4或3至4个碳原子的α-或β-位的直链或支链烷基,或R 6和R 7各自表示 氢原子或R 6和R 7一起是指α-或β-位亚甲基或另外的键。 新化合物具有孕激素和抗盐皮质激素的作用,并且适用于制备药物制剂,例如用于口服避孕和治疗绝经前,绝经期和绝经后症状。

    18 Norsteroids as selectively active estrogens
    15.
    发明授权
    18 Norsteroids as selectively active estrogens 失效
    18只小鼠作为选择性活性雌激素

    公开(公告)号:US06958327B1

    公开(公告)日:2005-10-25

    申请号:US10111933

    申请日:2000-11-02

    IPC分类号: A61K31/56 C07J1/00

    CPC分类号: C07J1/00

    摘要: The invention relates to novel 18-norsteroids (gonatrienes) of general formula (I), wherein R1, R2, R3, R6, R7, R8, R9, R11, R11′, R14, R15, R15′, R16, R17 and R17′ have the meaning cited in the description, and to the use of said compounds as pharmaceutical active ingredients. Said compounds exhibit a high affinity in vitro for estrogen receptor preparations of rat prostate and in an estrogen receptor preparation of rat uterus. Said compounds exhibit in vivo preferential activity on bones as compared to the uterus and/or significant activity with regard to stimulating the expression of 5HT2a-receptors and transporter molecules. The invention also relates to the production of said compounds, therapeutic use and galenic form of said compounds contained in the novel compounds of invention. The invention also relates to utilization of steroids based on the gonatriene molecular skeleton in order to treat estrogen deficiency-induced diseases and disorders, in addition to the use of said gonatriene structural component in the total structure of compounds which dissociate to produce enhanced estrogen activity in bone as compared to the uterus

    摘要翻译: 本发明涉及通式(I)的新颖的18-降胆固醇(高三烯),其中R 1,R 2,R 3,R 3, R 6,R 7,R 8,R 9,R 11,R 11,R 11, R 11,R 14,R 15,R 15',R 16, R 17和R 17'具有说明书中引用的含义,以及所述化合物作为药物活性成分的用途。 所述化合物在体外对大鼠前列腺的雌激素受体制剂和大鼠子宫的雌激素受体制剂中表现出高亲和力。 与刺激5HT2a受体和转运蛋白分子表达相关的子宫和/或显着活性相比,所述化合物在骨骼上表现出体内优先活性。 本发明还涉及所述化合物的生产,本发明新化合物中所含化合物的治疗用途和盖仑型形式。 本发明还涉及除了在分解以产生增强的雌激素活性的化合物的总体结构中使用所述三氢结构组分之外,还可以利用基于分子量分子骨架的类固醇来治疗雌激素缺乏诱导的疾病和病症 骨与子宫相比